全身糖皮质激素对重症社区获得性肺炎患者临床结局的影响:多中心回顾性研究
该多中心回顾性研究纳入2013年1月1日至2015年12月31日北京、山东、云南五家教学医院收治的132例重症社区获得性肺炎(SCAP)免疫功能正常成人及青少年患者,糖皮质激素组24例接受甲泼尼龙(0.6±0.1)mg×kg-1×d-1、(4.0±1.7)天,非糖皮质激素组108例。调整性别、年龄、合并症及经验性抗菌治疗后,糖皮质激素与晚期需升压药(OR=3.369,95%CI 1.369-6.133,P=0.035)、晚期需胰岛素治疗的高血糖(OR=4.738,95%CI 1.890-8.652,P=0.017)及30天死亡率(OR=2.187,95%CI 1.265-4.743,P=0.002)风险升高相关。作者结论认为短期低剂量全身糖皮质激素加重临床结局,不应常规用于SCAP患者。
要点
- 132例SCAP患者中糖皮质激素组24例使用甲泼尼龙(0.6±0.1)mg×kg-1×d-1、(4.0±1.7)天,非糖皮质激素组108例。
- 调整混杂后糖皮质激素与30天死亡率升高相关(OR=2.187,95%CI 1.265-4.743,P=0.002)。
- 糖皮质激素与晚期需升压药风险升高相关(OR=3.369,95%CI 1.369-6.133,P=0.035)。
- 糖皮质激素与晚期需胰岛素治疗的高血糖风险升高相关(OR=4.738,95%CI 1.890-8.652,P=0.017)。
- 作者结论:短期低剂量全身糖皮质激素加重SCAP临床结局,不应常规用于SCAP患者。
适用人群与场景
- 2013年1月1日至2015年12月31日北京、山东、云南五家教学医院收治的免疫功能正常成人及青少年社区获得性肺炎患者,最终纳入132例SCAP患者。
- 按病程中是否使用糖皮质激素分为糖皮质激素组24例和非糖皮质激素组108例。
处置流程与药物剂量
- 糖皮质激素组使用甲泼尼龙(0.6±0.1)mg×kg-1×d-1,疗程(4.0±1.7)天。
研究设计与关键结果
- 多中心回顾性研究,筛查3561例免疫功能正常成人及青少年CAP患者,最终132例SCAP患者纳入分析,糖皮质激素组24例、非糖皮质激素组108例。
- 糖皮质激素组甲泼尼龙剂量(0.6±0.1)mg×kg-1×d-1,疗程(4.0±1.7)天。
- 糖皮质激素组较非糖皮质激素组年龄更轻[70.5(59.0,75.0)岁 vs. 80.0(76.0,85.0)岁],男性比例更低[41.7%(10/24)vs. 72.2%(78/108)],心血管合并症更少[16.7%(4/24)vs. 42.6%(46/108)],脑血管病更少[0%(0/24)vs. 40.7%(44/108)],意识模糊更少[16.7%(4/24)vs. 40.7%(44/108)],COPD更多[41.7%(10/24)vs. 13.0%(14/108)],哮喘更多[25.0%(6/24)vs. 1.9%(2/108)],慢性肝病更多[8.3%(2/24)vs. 0%(0/108)],呼吸频率≥30次/分更多[33.3%(8/24)vs. 9.3%(10/108)],差异均有统计学意义(均P<0.05)。
- 糖皮质激素组较非糖皮质激素组指南推荐经验性抗菌治疗比例更高[50.0%(12/24)vs. 21.3%(23/108)],早期需无创通气比例更高[33.3%(8/24)vs. 7.4%(8/108)],晚期消化道出血更多[20.8%(5/24)vs. 4.6%(5/108)],早期需胰岛素治疗的高血糖更多[20.8%(5/24)vs. 1.9%(2/108)],晚期需胰岛素治疗的高血糖更多[37.5%(9/24)vs. 2.8%(3/108)],差异均有统计学意义(均P<0.05)。
- 调整性别、年龄、合并症及经验性抗菌治疗后,Logistic回归显示糖皮质激素与晚期需升压药风险升高相关(OR=3.369,95%CI 1.369-6.133,P=0.035),与晚期需胰岛素治疗的高血糖风险升高相关(OR=4.738,95%CI 1.890-8.652,P=0.017),与30天死亡率升高相关(OR=2.187,95%CI 1.265-4.743,P=0.002)。
证据类型、等级与局限
- 多中心回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,短期低剂量全身糖皮质激素加重SCAP患者临床结局,不应常规用于SCAP患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the impact of short-term, low-dose systemic glucorticosteroids treatment on the clinical outcomes in patients with severe community-acquired pneumonia (SCAP).
METHODS: A multi-center retrospective study was conducted. Data of patients hospitalized with SCAP in five teaching hospitals from Beijing, Shandong and Yunnan Provinces from January 1st, 2013 to December 31st, 2015 were reviewed. Patients were divided into steroids group and non-steroids group according to whether treated with glucorticosteroids during the disease course or not. Data of patients were reviewed, including gender, age, underlying disease, blood routine, biochemical examination and radiology findings (the worst value was recorded if there were more than one value), supportive treatment, complications (hyperglycemia needing insulin treatment and gastrointestinal bleeding) and clinical outcomes [early (0-3 days) treatment failure, late (4-14 days) treatment failure and 30-day mortality, treatment failure was defined as one of the followings: needing noninvasive or invasive ventilation, needing vasopressor use or death]. Univariate and multivariate Logistic regression was performed to evaluate the impact of short-term, low-dose systemic glucorticosteroids on the clinical outcomes in SCAP patients.
RESULTS: Overall, 3 561 immunocompetent adult and adolescent patients with community-acquired pneumonia (CAP) were screened, 132 SCAP patients were entered into final analysis, including 24 patients in steroids group and 108 patients in non-steroids group. The patients in steroids group were prescribed with methylprednisolone (0.6±0.1) mg×kg-1×d-1 for (4.0±1.7) days. Compared with patients in non-steroids group, patients in steroids group showed younger age [years old: 70.5 (59.0, 75.0) vs. 80.0 (76.0, 85.0)], less frequency of male [41.7% (10/24) vs. 72.2% (78/108)], less comorbidities with cardiovascular [16.7% (4/24) vs. 42.6% (46/108)] and cerebrovascular disease [0% (0/24) vs. 40.7% (44/108)], less confusion [16.7% (4/24) vs. 40.7% (44/108)]; more frequency of chronic obstructive pulmonary disease [COPD, 41.7% (10/24) vs. 13.0% (14/108)], asthma [25.0% (6/24) vs. 1.9% (2/108)], chronic hepatic disease [8.3% (2/24) vs. 0% (0/108)] and respiratory rate ≥ 30 times/min [33.3% (8/24) vs. 9.3% (10/108)] with significant differences (all P < 0.05), the proportion of guideline-based empirical antimicrobial therapy, early needing noninvasive ventilation, late gastrointestinal bleeding, early and late hyperglycemia needing insulin treatment were higher in steroids group than non-steroids group [50.0% (12/24) vs. 21.3% (23/108), 33.3% (8/24) vs. 7.4% (8/108), 20.8% (5/24) vs. 4.6% (5/108), 20.8% (5/24) vs. 1.9% (2/108), 37.5% (9/24) vs. 2.8% (3/108), all P < 0.05]. Adjusted by gender, age, comorbidities and empirical antimicrobial therapy, Logistic regression confirmed short-term, low-dose systemic glucorticosteroids was associated with higher risk for vasopressor usage [odds ratio (OR) = 3.369, 95% confidence interval (95%CI) = 1.369-6.133, P = 0.035], hyperglycaemia needing insulin treatment (OR = 4.738, 95%CI = 1.890-8.652, P = 0.017) in late stage and 30-day mortality (OR = 2.187, 95%CI = 1.265-4.743, P = 0.002).
CONCLUSIONS: Adjunctive treatment with short-term, low-dose systemic glucorticosteroids worsen the clinical outcomes and should not be used to SCAP patients routinely.
参考来源
- Chen L, Han X, Li Y, et al. [Impact of systemic corticosteroids on the clinical outcomes in patients with severe community-acquired pneumonia: a multi-center retrospective study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31441402. doi:10.3760/cma.j.issn.2095-4352.2019.07.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。